Cediranib (AZD2171, NSC-732208) is a potent VEGFR(KDR) inhibitor with an IC50 of <1 nM, and also inhibits FLT3/4 with an IC50 of 5 nM/≤3 nM. In addition, Cediranib also has similar inhibitory activities against c-Kit and PDGFRβ. The selectivity of VEGFR is 36 times, 110 times and 1000 times higher than PDGFR-α, CSF-1R and Flt3, respectively. Cediranib (AZD2171) can induce autophagosome accumulation. Phase 3.

 

Brand: BCM

 

Target: VEGFR; FLT; PDGFR; c-Kit; Autophagy

 

Signaling Pathways: Angiogenesis; Autophagy; Tyrosine Kinase/Adaptors

 

In Vitro: Cediranib is highly effective and dose-dependent in human transplanted tumor models. In addition,Cediranib can cause vascular degeneration in transplanted human lung cancer tumors. Cediranib overgrows bones, has an obstructive effect on the production of the corpus luteum in the ovaries, and inhibits physiological processes that depend on angiogenesis.

 

Melting Point: 135-138°C

 

Boiling Point: 626.6±55.0 °C(Predicted)

 

pKa: 16.14±0.30(Predicted)

 

Solubility: Soluble in DMSO; Soluble in Ethanol. Insoluble in Water.

 

GHS: GHS07

 

Isomeric SMILES: CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5  

 

InChIKey: XXJWYDDUDKYVKI-UHFFFAOYSA-N  

 

InChI: InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3 

 

Attribute
[Chem Name]	4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline
[Synonym]	Cediranib; AZD2171; NSC-732208
[CAS No.]	288383-20-0
[EINECS]	670-946-2
[MDL No.]	MFCD09954115
[Formula]	C25H27FN4O3
[Molecular]	450.51
[Form]	Off-white to light yellow powder
[Storage]	Sealed in dry. Store in freezer, under -20°C

Goods Tag